Sector Gamma AS Boosts Stock Position in Bio-Rad Laboratories, Inc. $BIO

Sector Gamma AS grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 28.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,829 shares of the medical research company's stock after buying an additional 4,000 shares during the period. Bio-Rad Laboratories accounts for 1.4% of Sector Gamma AS's portfolio, making the stock its 27th biggest holding. Sector Gamma AS owned 0.07% of Bio-Rad Laboratories worth $4,302,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in BIO. Caitong International Asset Management Co. Ltd lifted its position in shares of Bio-Rad Laboratories by 3,633.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company's stock valued at $27,000 after buying an additional 109 shares in the last quarter. Quarry LP purchased a new position in shares of Bio-Rad Laboratories in the first quarter valued at about $29,000. Allworth Financial LP lifted its position in shares of Bio-Rad Laboratories by 260.0% in the first quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock valued at $36,000 after acquiring an additional 104 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company's stock valued at $40,000 after acquiring an additional 79 shares in the last quarter. Finally, Headlands Technologies LLC lifted its position in shares of Bio-Rad Laboratories by 64.1% in the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock valued at $87,000 after acquiring an additional 139 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Trading Up 1.4%

Shares of BIO stock opened at $338.57 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The stock's 50-day moving average price is $294.27 and its 200-day moving average price is $261.27. The stock has a market capitalization of $9.16 billion, a price-to-earnings ratio of 28.86 and a beta of 0.97.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm had revenue of $651.60 million for the quarter, compared to analysts' expectations of $614.82 million. During the same period in the previous year, the firm posted $3.11 earnings per share. The business's revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on BIO. Zacks Research upgraded Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th. Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, August 22nd. Weiss Ratings restated a "sell (d+)" rating on shares of Bio-Rad Laboratories in a research report on Tuesday, October 14th. Finally, Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.